Passer au contenu principal Atteindre le pied de page
Dhenne Avocats
  • Dhenne Avocats
  • Team
  • Fields of expertise
  • Our services
  • Blog
  • Glossary
  • Contact
  • Join us
    • fr
    • en
Back to blog

Category : UPC

5 September 2026
Portfolio strategy and the UPC: where the value of life sciences assets lies
10 September 2026
The launch letter before the UPC: what generics and biosimilars should write to avoid creating urgency
  • Application for a preliminary injunction
  • Patents
  • UPC
  • Jurisprudence
  • Pharmaceuticals
5 September 2026
Portfolio strategy and the UPC: where the value of life sciences assets lies
  • Patents
  • UPC
  • Pharmaceuticals
5 September 2026
Merz v. Viatris on appeal: urgency remains decisive, but not every signal is urgent
  • Application for a preliminary injunction
  • UPC
  • Pharmaceuticals
4 September 2026
UPC and life sciences: the first strategic lessons
  • UPC
  • Pharmaceuticals
4 September 2026
The UPC's long-arm jurisdiction: how far the arm reaches, where the effect stops
  • Patents
  • Litigation
  • UPC
3 September 2026
Imminent infringement before the UPC: the new geography of pharmaceutical risk
  • Application for a preliminary injunction
  • UPC
  • Pharmaceuticals
3 September 2026
The PMAC Rules: patent arbitration through the FRAND lens
  • Patents
  • FRAND
  • UPC
2 September 2026
The UPC did not end parallel litigation: it turned it into a weapon
  • Litigation
  • Forum shopping
  • UPC
1 September 2026
Damages before the UPC: from compensation to a market reference
  • Litigation
  • Damages and interests
  • UPC
31 August 2026
Forum shopping before the UPC: the map, the language and Article 33
  • Litigation
  • Forum shopping
  • UPC
30 August 2026
Anti-anti-suit injunctions before the UPC: Europe strikes back
  • Application for a preliminary injunction
  • FRAND
  • UPC
30 August 2026
UPC evidence preservation orders: the UPC saisie in practice
  • Patents
  • UPC
  • Saisie-contrefaçon
24 February 2025
The UPC's first FRAND decision: Panasonic v Oppo, and what came next
  • FRAND
  • UPC
30 July 2024
Sanofi v. Amgen: the UPC's first revocation action and therapeutic antibody patentability, from revocation to reversal
  • Patentability
  • UPC
  • Pharmaceuticals
29 July 2024
Comparable licenses before the UPC: compelled production and confidentiality clubs
  • Patents
  • FRAND
  • UPC
29 July 2024
UPC’s Order to Produce Evidence: Huawei vs. Netgear
  • Patents
  • FRAND
  • UPC
22 July 2024
The UPC’s first ruling on an infringement action by the Paris local division
  • Patents
  • UPC
6 May 2024
UPC and Proportionality: Will the EU enters through the back door? (From 10xGenomics case to UPC “seizure”)
  • Patents
  • UPC
  • Saisie-contrefaçon
30 April 2024
Release of a treaty on patent law co-authored by Matthieu Dhenne
  • Patents
  • UPC
4 April 2024
UPC “seizure” Part IV: the appeal against the “seizure” order
  • Patents
  • UPC
  • Saisie-contrefaçon
22 March 2024
UPC “seizure” Part III: the “C-Kore” case
  • Patents
  • UPC
  • Saisie-contrefaçon
18 March 2024
UPC seizure Part II: the “OERLIKON” case
  • Patents
  • UPC
  • Saisie-contrefaçon
5 June 2023
UPC: brief thoughts from a French “UPC Representative”
  • Patents
  • UPC
23 April 2023
Conflicts between UPCA and national laws: a dangerous riddle?
  • Patents
  • UPC
1 March 2023
Some light for the sunrise: 5 questions for 5 French UPC judges
  • Patents
  • UPC
White Dhenne Lawyer Logo

The French Law Firm dedicated to Patent Litigation

  • +33 (0)1 71 60 61 46
  • contact@dhenne-avocats.fr
  • LinkedIn
  • X ↗
  • 7, rue Commines
    75003 PARIS
© Dhenne Avocats 2026. All rights reserved
  • Legal notice
  • Cookie policy
  • Privacy policy
  • Design lilian_bruerre
  • Development / Integration Sea Dev and Sun